Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Cancer Related Cognitive Decline × Docetaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 425 Carcinoma, Non-Small-Cell Lung 388 Prostatic Neoplasms 253 Lung Neoplasms 156 Stomach Neoplasms 124 Neoplasms 100 Squamous Cell Carcinoma of Head and Neck 98 Head and Neck Neoplasms 82 Neoplasm Metastasis 80 Esophageal Neoplasms 65 Ovarian Neoplasms 51 Urinary Bladder Neoplasms 38 Pancreatic Neoplasms 36 Sarcoma 35 Nasopharyngeal Carcinoma 32 Triple Negative Breast Neoplasms 28 Carcinoma, Squamous Cell 28 Carcinoma, Ovarian Epithelial 25 Adenocarcinoma of Lung 25 Adenocarcinoma 25 Esophageal Squamous Cell Carcinoma 23 Adenocarcinoma Of Esophagus 23 Carcinoma, Transitional Cell 22 Recurrence 20 Fallopian Tube Neoplasms 19 Breast Neoplasms, Male 19 Parkinson Disease 4, Autosomal Dominant Lewy Body 18 Melanoma 17 Carcinoma 17 Unspecified Adult Solid Tumor, Protocol Specific 16

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡